Impact of Melatonin on IVF/ICSI Outcomes in Prospective Poor Responders

Impact of Melatonin Adjuvant Therapy on IVF/ICSI Outcomes in Prospective Poor Responders: A Double-blind, Randomized, Placebo-controlled Trial

Status

UNKNOWN

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02993588

Enrollment

100

Registered

2016-12-15

Start date

2016-12-31

Completion date

Unknown

Last updated

2016-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

In Vitro Fertilization, Poor Ovarian Response

Keywords

Melatonin, IVF/ICSI, Poor ovarian response

Brief summary

The purpose of this study is to investigate the impact of melatonin administration on in vitro fertilization (IVF/ICSI) outcomes namely the total number and quality of the oocytes and embryos in the prospective poor responders.

Detailed description

The prospective poor responders have been associated with lower number and poorer oocyte quality. Melatonin is suggested to have antioxidative effects which may contribute to improving the IVF/ICSI outcomes in this group of patients who expected to have poor outcomes. However, the expected beneficial effects of melatonin have not yet been investigated. The purpose of this study is to investigate the impact of melatonin administration on IVF/ICSI outcomes namely the total number and quality of the oocytes and embryos in the prospective poor responders. A randomized, double-blinded, placebo-controlled study is used to investigate the impact of melatonin on the IVF/ICSI outcomes.

Interventions

DRUGMelatonin

Melatonin 6 mg tablet once daily

OTHERPlacebo

one tablet once daily

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender

FEMALE

Age

30 Years to 42 Years

Healthy volunteers

Inclusion criteria

* Prospective poor responder with AMH \< 1 ng/ml and AFC \< 8 (in both ovaries).

Exclusion criteria

* Severe male factor infertility.

Design outcomes

Primary

Measure	Time frame
Total number of retrieved mature oocytes	On the day of oocyte retrieval procedure

Countries

Egypt

Contacts

Primary ContactOsama Abdalmageed, MD

drosamast1981@gmail.com1007972027

Backup ContactOsama Abdalmageed, MD

drosamast1981@gmail.com882102204

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026